I See Two Very Different Opportunities in This Overbought Market
I’m getting into a legacy technology stock and an up-and-coming biopharma. Here’s why.
I’m getting into a legacy technology stock and an up-and-coming biopharma. Here’s why.
Earnings growth better than 50%, a forward multiple around 12 and an analyst target roughly a third higher.
Let’s answer a reader’s important question today about the Nasdaq.
As AI trade continues to enter more and more radical territory, I’m bracing for a bad ending.
Let’s check the latest from Iran, the OECD’s dire forecast, another round of tariffs … and my Marvell miss.
We’re being opportunistic today, but we still like the company’s long-term prospects.
Lebanon’s ceasefire, HPE earnings, Google’s capital raise, and other headlines are moving stocks this morning.
Talks drag on, May Manufacturing PMI data, more memory chip pain, and other headlines are moving stocks this morning.
Dell is flying on AI demand while Costco struggles with high oil prices.
We’re also lifting our checkpoint level and identifying a potential pick-up point.